A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts

MLA

Garcia-Manero, G., et al. A Phase 1b/2b Multicenter Study of Oral Panobinostat plus Azacitidine in Adults with MDS, CMML or AML with Less than or Equal to 30% Blasts. Dec. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.core.ac.uk....b255920b78c8f42dc4e92fc9813e17ff&authtype=sso&custid=ns315887.

APA

Garcia-Manero, G., Sekeres, M. A., Egyed, M., Breccia, M., Graux, C., Cavenagh, J. D., Salman, H., Illes, A., Fenaux, P., DeAngelo, D. J., Stauder, R., Yee, K., Zhu, N., Lee, J.-H., Valcarcel, D., MacWhannell, A., Borbenyi, Z., Gazi, L., Acharyya, S., … Ottmann, O. (2017). A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts.

Chicago

Garcia-Manero, G, M A Sekeres, M Egyed, M Breccia, C Graux, J D Cavenagh, H Salman, et al. 2017. “A Phase 1b/2b Multicenter Study of Oral Panobinostat plus Azacitidine in Adults with MDS, CMML or AML with Less than or Equal to 30% Blasts,” December. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.core.ac.uk....b255920b78c8f42dc4e92fc9813e17ff&authtype=sso&custid=ns315887.